New data demonstrates sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products

New data demonstrates sandoz’ etanercept and rituximab biosimilar candidates bioequivalent to originator products [1]

Publish Date:

Jeudi, 9 JUIN 2016 - 10:00am

Holzkirchen, June 9, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies comparing its biosimilar etanercept and rituximab candidates with the originator products - Enbrel®*** and MabThera®**** respectively. In both studies, the primary endpoints of achieving PK bioequivalence were met. The studies were presented at the Annual European Congress of Rheumatology (EULAR 2016) in London.1,2 Etanercept and rituximab are indicated to treat autoimmune diseases such as rheumatoid arthritis. Rituximab is also indicated to treat hematological cancers like follicular lymphoma.